JUPITER: A few words of caution

Circulation: Cardiovascular Quality and Outcomes

Volumn 2, Issue 3, 2009, Pages 286-288

  Vaccarino, Viola ^a,c   Bremner, J Douglas ^b   Kelley, Mary E ^d  

^a Division of Cardiology   (United States)

^b Department of Psychiatry and Behavioral Sciences ^*  (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG COST; DRUG INDICATION; DRUG SAFETY; HAZARD RATIO; HEART INFARCTION; HOSPITALIZATION; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; STROKE; UNSTABLE ANGINA PECTORIS; ARTICLE; HYPERTENSION; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77949880455     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.109.850404     Document Type: Short Survey

References (18)

1. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. the JSG. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008;359:2195-2207.
2. Weintraub H, Gagarin D. Predicting the potential effect of JUPITER. Cardiology Today, November 2008.
3. Davis EC. Should statins be available for everyone? Los Angeles Times, December 22, 2008.
4. Spatz ES, Canavan ME, Desai MM. From Here to JUPITER: Identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2009;2:41-48.
5. Hlatky MA. Expanding the orbit of primary prevention - moving beyond JUPITER. N Engl J Med. 2008;359:2280-2282.
6. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289:2554-2559.
7. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
8. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238-1245.
9. Eyre H, Kahn R, Robertson RM. Preventing cancer, cardiovascular disease, and diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Diabetes Care. 2004;27:1812-1824. (Pubitemid 38857468)
10. Levi J, Segal LM, Juliano C. Prevention for a healthier America: Investments in disease prevention yield significant savings, stronger communities: Trust for America's Health. Issue Report July 2008. http://healthyamericans.org/reports/prevention08/. Accessed April 13, 2009.
11. Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
12. Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G. Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol. 2008;61:241-246.
13. Montori VM, Devereaux PJ, Adhikari NKJ, Burns KEA, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203-2209.
14. Berwick DM. Disseminating innovations in health care. JAMA. 2003;289:1969-1975.
15. Mueller PS, Montori VM, Bassler D, Koenig BA, Guyatt GH. Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med. 2007;146:878-881.
16. Landefeld CS, Steinman MA. The neurontin legacy - marketing through misinformation and manipulation. N Engl J Med. 2009;360:103-106.
17. Jorgensen A, Maric K, Tendal B, Faurschou A, Gotzsche P. Industrysupported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions. BMC Med Res Methodol. 2008;8:60.
18. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-928.